GlassScriptPhysician profile
Nitnoy K Badgley
NPI 1194844951
$4,332.17
in general payments reported to CMS, 2019-2025
33 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.81 · 2022: $1,011 · 2023: $738 · 2024: $1,115 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,250.04 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $433.72 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $324.28 | 2022-2025 | Dupixent |
| Verona Pharma, INC. | $249.26 | 2025 | Ohtuvayre |
| Genzyme Corporation | $233.89 | 2022-2024 | |
| Baxter Healthcare | $196.01 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Insmed, INC. | $171.02 | 2022-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $169.79 | 2022-2024 | Yupelri |
| Pulmonx Corporation | $163.06 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Amgen INC. | $158.67 | 2022-2025 | Tezspire |
| Harmony Biosciences LLC | $90.79 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $83.67 | 2022-2025 | Opsumit, Uptravi |
| Axsome Therapeutics, INC. | $79.63 | 2023-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.32 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $67.32 | 2022-2023 | Glassia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Invivyd INC | $60.41 | 2025 | Pemgarda |
| Avadel Cns Pharmaceuticals, LLC | $58.60 | 2024-2025 | Lumryz |
| Viatris Specialty LLC | $50.37 | 2025 | Yupelri |
| Vanda Pharmaceuticals INC. | $46.01 | 2022 | |
| Grifols USA, LLC | $42.91 | 2022-2024 | Prolastin-C Liquid |
| Electromed, INC. | $42.28 | 2022-2025 | Smartvest |
| Shionogi INC | $35.76 | 2022 | |
| Philips North America LLC | $28.68 | 2022-2025 | Vest Therapy Und |
| Advanced Respiratory, INC | $27.81 | 2021 | |
| Azurity Pharmaceuticals, INC. | $27.59 | 2025 | Alvesco |
| Mallinckrodt Hospital Products INC. | $24.26 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $24.26 | 2023 | |
| Tactile Systems Technology INC | $22.74 | 2022 | |
| United Therapeutics Corporation | $20.79 | 2025 | Tyvaso |
| Astellas Pharma US INC | $18.74 | 2022 | |
| Pharming Healthcare, INC. | $17.00 | 2024 | Ruconest |
| Vifor Pharma, INC. | $16.87 | 2024 | Zemaira |
| Paratek Pharmaceuticals, INC. | $16.62 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitnoy Badgley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.